Dose Insider / Outsourcing pharmacies / SCA Pharmaceuticals

SCA PharmaceuticalsFDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

SCA Pharmaceuticals in Little Rock, Arkansas is registered with FDA as a 503B outsourcing facility, first on December 13, 2013 and most recently on October 26, 2026. FDA last inspected it on October 30, 2025 and issued a Form 483 with 4 observations.

4 observationsin the Form 483 of FDA’s inspection on October 30, 2025
Observations in the last Form 483FDA inspection reports of registered outsourcing facilitiesSCA Pharmaceuticals4Median facility5Most in one report16Observations in the lastForm 483FDA inspection reports of registered outsourcingfacilitiesSCA Pharmaceuticals4Median facility5Most in one report16

SCA Pharmaceuticals had fewer observations than the median inspected facility.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilitySCA Pharmaceuticals
LocationLittle Rock, Arkansas
Type503B outsourcing facility
Registered sinceDecember 13, 2013
Latest registrationOctober 26, 2026
Last FDA inspectionOctober 30, 2025
Inspection dates10/20/2025 to 10/30/2025
Form 483Issued, 4 observations
FDA action after the inspectionWarning Letter Issued 9/14/202
Compounds sterile drugs from bulkYes
FDA warning letters on GLP-1 drugs0

What did FDA’s investigators observe?

The Form 483 from the inspection of 10/30/2025 lists 4 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2

What the observation is aboutObservations
Sterility and aseptic processing3

FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.

Has this facility recalled any drugs?

FDA’s enforcement reports list 44 recalled products from this facility, from April 28, 2015 to December 14, 2020: 4 in Class I, 40 in Class II. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2020-12-14IIVasopressin 20 Units added to 0.9% Sodium Chloride 100 mL Rx OnlySubpotent drug.
2018-06-29IIBuffered Lidocaine 1% with Sodium Bicarbonate Injection for Local AnesSubpotent Drug: Stability data does not support the current expiration dating of 55 days after compounding.
2017-10-19IIfentaNYL as citrate 2 mcg / mLLack Of Assurance Of Sterility.
2017-10-19IIoxyTOCIN 30 units added to Lactated Ringers 500 mL BagLack Of Assurance Of Sterility.
2017-10-19IIfentanyl as citrate 2 mcg per mL BUPIvacaine HCl 0.125% (Total FentaNYLack Of Assurance Of Sterility.
2017-10-19IIHYDROmorphone HCL 1 mg per mL in 0.9% Sodium Chloride 25 mL Fill in 30Lack Of Assurance Of Sterility.
2017-10-19IImorphine sulfate 1 mg per mL in 0.9% Sodium Chloride a) Total Volume 1Lack Of Assurance Of Sterility.
2017-10-19IISUCcinylcholine 20 mg per mLLack Of Assurance Of Sterility.

The table shows 8 of the 44 recalls; the rest are in FDA’s enforcement reports.

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

3 of the 100 facilities on FDA’s list are in Arkansas. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Form FDA 483, inspection of SCA Pharmaceuticals, 10/20/2025 to 10/30/2025. fda.gov
  3. FDA. Drug recall enforcement reports for SCA Pharmaceuticals, read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider